- Home
- PFSA vs BOLD Comparison
PFSA vs BOLD Comparison
Compare PFSA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFSA
- BOLD
- Stock Information
- Founded
- PFSA 2009
- BOLD 2018
- Country
- PFSA United States
- BOLD United States
- Employees
- PFSA N/A
- BOLD N/A
- Industry
- PFSA Medical/Dental Instruments
- BOLD
- Sector
- PFSA Health Care
- BOLD
- Exchange
- PFSA Nasdaq
- BOLD Nasdaq
- Market Cap
- PFSA 25.1M
- BOLD 25.5M
- IPO Year
- PFSA N/A
- BOLD 2024
- Fundamental
- Price
- PFSA $0.29
- BOLD $1.20
- Analyst Decision
- PFSA
- BOLD Buy
- Analyst Count
- PFSA 0
- BOLD 4
- Target Price
- PFSA N/A
- BOLD $4.00
- AVG Volume (30 Days)
- PFSA 15.4M
- BOLD 79.7K
- Earning Date
- PFSA 08-14-2025
- BOLD 11-06-2025
- Dividend Yield
- PFSA N/A
- BOLD N/A
- EPS Growth
- PFSA N/A
- BOLD N/A
- EPS
- PFSA N/A
- BOLD N/A
- Revenue
- PFSA $75,000.00
- BOLD N/A
- Revenue This Year
- PFSA N/A
- BOLD N/A
- Revenue Next Year
- PFSA N/A
- BOLD N/A
- P/E Ratio
- PFSA N/A
- BOLD N/A
- Revenue Growth
- PFSA 66.67
- BOLD N/A
- 52 Week Low
- PFSA $0.27
- BOLD $1.00
- 52 Week High
- PFSA $5.50
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- PFSA N/A
- BOLD 63.62
- Support Level
- PFSA N/A
- BOLD $1.10
- Resistance Level
- PFSA N/A
- BOLD $1.19
- Average True Range (ATR)
- PFSA 0.00
- BOLD 0.05
- MACD
- PFSA 0.00
- BOLD 0.00
- Stochastic Oscillator
- PFSA 0.00
- BOLD 62.50
About PFSA Profusa Inc. Common Stock
Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.